AI Science Tracker
EN

University of Miami Miller School of Medicine

1 discovery from 2023

Discoveries

Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI

Source check: Source checked. Not independent scientific confirmation.

Finding: Adaptive-LASSO and logistic models used prostate MRI and clinical features to distinguish low-risk biopsy lesions in a selected trial-derived cohort. The best reported AUC was 0.95.

Technology: Habitat-risk segmentation and radiomics with adaptive-LASSO/logistic models classified low-risk prostate lesions from pre-biopsy clinical/MRI features; 231 cores/78 men and bootstrap optimism correction, best AUC .95. Small selected trial-derived cohort, no external validation.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Habitat-risk segmentation and radiomics with adaptive-LASSO/logistic models classified low-risk prostate lesions from pre-biopsy clinical/MRI features; 231 cores/78 men and bootstrap optimism correction, best AUC .95. Small selected trial-derived cohort, no external validation.
Test and result
The analysis included 231 biopsy cores from 78 men and used bootstrap correction for model optimism.
Limitation / still unknown
A small selected cohort and internal resampling limit what the result establishes about other patients.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.mdpi.com/2072-6694/15/21/5240

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: other. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.